Mind Medicine (MindMed) Inc.,一家根據不列顛哥倫比亞省法律成立的公司("公司”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “持有人”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [●] common shares, without par value (the “普通股份。股份有機和可持續農業實踐的不斷增加促進了對有機肥料的需求,包括派生自磷酸鹽岩的肥料。有機磷酸鹽岩經常被營銷爲不僅可提供磷還有助於整體土壤健康的肥料。”和所有此類股份,皆稱爲「權證」權證 股票)按照每股$0.001的行權價格行使(隨時根據所述進行調整 第九部分 本Warrants中規定的行使價格)在交出本普通股權證購買權證(包括任何以此作爲交換、轉讓或更換而發行的普通股購買權證)後,“權證)在本日起的任何時間按照以下條款和條件行使可兌換普通股的權利,並交回本認股權證(包括在此換髮、轉讓或替換本權證的任何認股權證,稱爲“原始發行日期受以下條款和條件的約束:
如果在行權日後第五個(5個)交易日結束時,公司未能按照《5(a)條》規定的方式向持有人交付代表所需認股權股數的證書,或未能將持有人的餘額帳戶與DTC成立,使其獲得相應數量的認股權股份,且如果在第五個(5個)交易日後並在收到該等認股權股份之前,持有人購買(在市場公開交易或其他方式下)普通股以完成將持有人預期從行權中獲得的認股權股票的銷售的交割(「買入」),則公司應在持有人要求之後的兩個(2個)交易日內,迅速履行其交付持有人或其指定人代表的證券或使用DTC將此類認股權股票計入持有人餘額帳戶的義務,以及支付現金給持有人,金額相當於買入中持有人所購買的普通股總購買價格(包括經紀佣金,如有)超過行權日的一個普通股的收盤價和買入中所購買的普通股數的乘積的餘額。th) Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to 第5(a)節 or fails to credit the Holder’s balance account with DTC for such number of Warrant Shares to which the Holder is entitled, and if after such fifth (5th) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) Common Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “買入如本公司未能在股東要求後的兩(2)個交易日內,立即兌現其交付股東或其指定人一份或多份代表該認股權證股份的證書或向DTC爲該認股權證股份進行資金結算,並向股東支付金額,金額等於(如有)購買強制購回普通股的總購買價格(包括經紀佣金,如果有)超過(如有)購買強制購回普通股的數量乘以(買入當天的普通股收盤價的乘積)。
按比例分配. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Shares for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Shares covered by the preceding paragraph) or (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each case, “分發財產”), then, upon any exercise of this Warrant that occurs after the record date fixed for determination of shareholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date without regard to any limitation on exercise contained therein.
(c)
基本交易. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the shareholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a
6
series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of share capital tender shares representing more than 50% of the voting power of the share capital of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the share capital of the Company (except for any such transaction in which the shareholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction), provided, however, that the foregoing shall not include transactions for which the primary purpose is raising capital, or (v) the Company effects any reclassification of the Common Shares or any compulsory share exchange pursuant to which the Common Shares are effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of Common Shares covered by 本條款第9(a)節(公司承擔義務賠償)規定的權利和義務之外,如果公司或其代理未能履行在交割日交付授權股份的義務而不是由於TD Cowen的原因,公司同意(i)保護TD Cowen免失或對TD Cowen遭受的任何損失、索賠、損害、合理且可證明的費用(包括律師費和其他費用)承擔責任,並(ii)支付任何佣金、折價或其他報酬給TD Cowen(無需重複)。如未發生違約情況,TD Cowen將享有按照協議應得到的佣金、折價或其他報酬。 在本期權有效之後的任何根本交易發生時,持有人有權在行使本期權時接收與根本交易發生時其如果是本期權能全部行使時應當接收的狀態相同數量和種類的證券、現金或財產(包括暫時擱置的任何分配或購買權)。基本交易”), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the “Alternate Consideration”). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash, solely marketable securities, or a combination of cash and marketable securities, and the Company provides for the simultaneous 「cashless exercise」 of this Warrant pursuant to 第10節
修改和終止。 below or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. In the event the Holder does not exercise this Warrant as contemplated by the foregoing sentence, this Warrant shall be deemed exercised in full without regard to any limitations on exercise contained herein pursuant to the 「cashless exercise」 provision in 第10節
修改和終止。 在此基礎上,經過此類基本交易完成生效日期。
Shares the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding Common Shares as reflected in (x) the Company’s most recent Quarterly Report on Form 10-Q, Annual Report on Form 10-k and Current Reports on Form 8-k or other public filing with the Commission, as the case may be, (y) a more recent public announcement by the Company or (z) any other notice by the Company or the Transfer Agent setting forth the number of Common Shares outstanding. Upon the written request of the Holder, the Company shall within one Trading Day confirm in writing or by electronic mail to the Holder the number of Common Shares then outstanding. In any case, the number of outstanding Common Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding Common Shares was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% of the issued and outstanding Common Shares immediately after giving effect to the issuance of the Common Shares issuable upon exercise of this Warrant; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this 第11(a)條, the aggregate number of Common Shares or voting securities beneficially owned by the Holder and any other Attribution Party shall include the Common Shares issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Common Shares which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) the exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Shares, including without limitation any debt, preferred shares, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any other Attribution Party. No prior inability to exercise this Warrant will have any effect on the applicability of the provisions for any subsequent exercise. The provisions of this paragraph will be construed and implemented in a manner otherwise than in strict conformity with its terms to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this paragraph or to make changes or supplements necessary or desirable to properly give effect such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant.